ライフサイエンスコーパス: mCi

1 Diagnostic doses were 1.0 mCi (37 MBq) in all; therapeutic doses were 150 and 30 m

2 mCi/m(2) (277.5 MBq/m(2); level 3), and 10.0 mCi/m(2) (370 MBq/m(2); level 4).

3 We recommend the dose of 2 x 10.0 mCi/m(2) 1 week apart per cycle for phase 2 studies.

4 an administered activity of 3.89 GBq (105.0 mCi) was obtained, resulting in tumor and lung absorbed

5 Approximately 74 MBq (2.0 mCi) of (99m)Tc(CO)3(NTA) were coinjected with approxima

6 : 2.5 mCi/m(2) (92.5 MBq/m(2); level 1), 5.0 mCi/m(2) (185 MBq/m(2); level 2), 7.5 mCi/m(2) (277.5 MB

7 of 2-[18F]FA (1.6 MBq/kg or 0.043 +/- 0.002 mCi/kg).

8 radioactivity of 1,222 GBq/micromol (33,024 mCi/micromol; n = 6) at the end of synthesis.

9 ivity of 181.7 +/- 1.1 MBq/mg (4.91 +/- 0.03 mCi/mg).

10 nesthetized and injected with [18F]FEAU (0.1 mCi per mouse); this is followed 2 h after injection by

11 ransit study was performed with 3.7 MBq (0.1 mCi) of (111)In-DTPA in 15 mL of water.

12 udy followed, with ingestion of 3.7 MBq (0.1 mCi) of (111)In-DTPA in 300 mL of water.

13 d TSC in 0.05 mL normal saline: 3.7 MBq (0.1 mCi) on the morning of surgery (1-d protocol) or 18.5 MB

14 l evaluable dogs conditioned with 1.4 to 2.1 mCi/kg Bi-anti-CD45 or 2.0 to 2.7 mCi/kg Bi-anti-TCRalph

15 icle was labeled with the PET tracer 64Cu (1 mCi/0.1 mg nanoparticles) to yield a PET, magnetic reson

16 nephosphonate (EDTMP) 0.5, 0.5, 0.5, 0.75, 1 mCi/kg.

17 sterile preparation of the operative field 1 mCi of Tc-99 unfiltered was administered by a subareolar

18 h after injection of (18)F-FDG (37 MBq/kg [1 mCi/kg]).

19 per month decreased (10,746 vs. 7,174 mCi [1 mCi = 37 MBq], P < 0.0001), as did the mean (99m)Tc admi

20 28-day cycle in combination with (153)Sm (1 mCi/kg) on day 1.

21 Even with the 1-mCi dose, the radioactive blue dye produced significantl

22 specific activity of 127-370 MBq/mg (3.4-10 mCi/mg) after chromatographic purification.

23 R) chamber coated with radioactive Ni-63 (10 mCi) that fills the CR chamber with a bipolar ionic atmo

24 the range of 300-370 MBq (approximately 8-10 mCi) contribute to image interpretation and justify the

25 the range of 300-370 MBq (approximately 8-10 mCi) do not affect the relative function measurements or

26 tive ions derived from purified air and a 10 mCi (63)Ni foil.

27 , and a single-dose injection of 370 MBq (10 mCi) 131I-TM-601 (0.25-1.0 mg of 131I-TM-601) 2-4 wks af

28 O-water, which was followed by a 370-MBq (10 mCi) dose of 18F-FDG.

29 were intravenously administered 370 MBq (10 mCi) of (123)I-MIP-1072 and (123)I-MIP-1095 2 wk apart i

30 he intravenous administration of 370 MBq (10 mCi) of (18)F-DCFBC.

31 ion of either 111 MBq (3 mCi) or 370 MBq (10 mCi) of florbetapir F 18 in patients with Alzheimer's di

32 tudy involving a labeled dose of 370 MBq (10 mCi) of fluorine 18 fluorodeoxyglucose is estimated to i

33 ts received a dosimetric dose of 370 MBq (10 mCi).

34 n after injection of the tracer (370 MBq [10 mCi]).

35 With an injected dose of 10 mCi (370 MBq) and a 1-hour voiding interval, a patient w

36 A single dose of 10 mCi 131I-TM-601 was well tolerated for 0.25 to 1.0 mg TM

37 ntibody labeled with 185 to 370 Mbq (5 to 10 mCi) [131I]-tracer for dosimetry purposes followed 10 da

38 tolerated; the maximum-tolerated dose was 10 mCi.

39 , or 1.0 mg of TM-601), each labeled with 10 mCi of 131I.

40 between the 111-MBq (3-mCi) and 370-MBq (10-mCi) dose in the visual rating or SUVr.

41 f lesional doses being noted using fixed 100 mCi radioactivities of I-131, no dose-effective relation

42 ctive as high-dose radioiodine (3.7 GBq [100 mCi]) for treating patients with differentiated thyroid

43 tution phase II study, administration of 100 mCi of 131I-m81C6 to recurrent malignant glioma patients

44 In this phase II trial, 100 mCi of 131I-m81C6 was injected directly into the surgica

45 e than patients staged pN1 (median 30 vs 100 mCi, P < 0.0001).

46 valent 48-h activity limits of 3.72 GBq (101 mCi) and 2.45 GBq (66.2 mCi), respectively.

47 dian, 4,033 MBq [109 mCi] vs. 3,811 MBq [103 mCi], P=0.01) but did not differ with respect to sex, hi

48 se was 71.6 mCi (2649.2 MBq; range, 36.6-105 mCi; range, 1354.2-3885 MBq).

49 /- SD], median (131)I dose of 3,996 MBq [108 mCi]).

50 d activity of (131)I (median, 4,033 MBq [109 mCi] vs. 3,811 MBq [103 mCi], P=0.01) but did not differ

51 (maximum, 485 MBq [0.15 mCi/kg; maximum, 12 mCi]) of (18)F-FDG with imaging initiated approximately

52 es ranging from 492 to 1,160 mCi (median, 12 mCi/kg).

53 (> or = 100 mL/min/1.73 m2) was 131I-MIBG 12 mCi/kg, carboplatin 1,500 mg/m2, etoposide 1,200 mg/m2,

54 ematopoietic stem cells (n = 16) received 12 mCi/kg.

55 treatment with [(131)I]MIBG greater than 12 mCi/kg or with a total dose greater than 500 mCi.

56 R cohort, at the initial dose level using 12 mCi/kg of 131I-MIBG and reduced chemotherapy, one in six

57 nt consisted of three cycles of 4.4 GBq (120 mCi) (90)Y-edotreotide each, once every 6 weeks.

58 with (131)I-ch81C6 doses up to 4.44 GBq (120 mCi), including 35 with newly diagnosed tumors (strata A

59 /- 125.8]; mean specific radioactivity, 1200 mCi/mmol +/- 714 [44.4 GBq/mmol +/- 26.4]).

60 (131)I in the range of 2.04-4.81 GBq (55-130 mCi), yields of 59.9% +/- 7.9% (mean +/- SD) at specific

61 We synthesized [(14)C]TETS (14 mCi/mmol, radiochemical purity >99%) by reacting sulfami

62 The MTA was less than 5.18 GBq (140 mCi) in 3%, less than 7.4 GBq (200 mCi) in 8%, and less

63 ed RAI activities of less than 5.18 GBq (140 mCi) rarely exposed blood to more than 200 cGy except in

64 thyroid cancer; median dose, 5,217 MBq [141 mCi]).

65 t-based injected activity (5.3 MBq/kg [0.144 mCi/kg]), fixed acquisition durations (3 min/field of vi

66 received 5.5 MBq/kg (maximum, 485 MBq [0.15 mCi/kg; maximum, 12 mCi]) of (18)F-FDG with imaging init

67 After allowing for (11)C decay, 555 MBq (15 mCi) of (18)F-FDG were administered and repeated whole-b

68 r a standard single injection of 555 MBq (15 mCi) will result in an effective dose equivalent of 5.9

69 (99m)Tc-Glucarate (555 MBq [15 mCi]) was injected 30 min after reperfusion and was foll

70 nitive impairment (MCI; n = 13) (555 MBq [15 mCi], 90-min scan, and arterial blood sampling).

71 R-CHOP, responders received two doses of 15 mCi/m(2) (555 MBq/m(2)) (90)Y-epratuzumab tetraxetan adm

72 (90)Yttrium ((90)Y; 15 mCi/m(2))/(111)In (5 mCi)-DOTA-biotin was injected 24 ho

73 breast tissue associated with a 5.6-GBq (150 mCi) ablation treatment may range from 0.35 to 0.55 Gy,

74 n was most apparent after therapies with 150 mCi.

75 mCi]; range, 12.1 to 42.7 Gbq [328 to 1,154 mCi]) to deliver 25 to 27 Gy to the critical normal orga

76 P. anubis; 166.5 MBq +/- 43.0 (4.50 +/- 1.16 mCi) of 11C-CUMI-101 were injected as an intravenous bol

77 [(131)I]MIBG doses ranging from 492 to 1,160 mCi (median, 12 mCi/kg).

78 c used per month decreased (10,746 vs. 7,174 mCi [1 mCi = 37 MBq], P < 0.0001), as did the mean (99m)

79 rwent preoperative imaging using 666 MBq (18 mCi) of (99m)Tc-folate.

80 relapsed neuroblastoma were treated with 18 mCi/kg (131)I-MIBG on a phase I/II protocol.

81 ic stem cells (n = 148) were treated with 18 mCi/kg of 131I-MIBG.

82 I]MIBG administered ranged from 492 to 3,191 mCi.

83 n=29) were injected with NC100692 (1.5+/-0.2 mCi IV) at different times after femoral occlusion (1, 3

84 fter injection of 192 +/- 7 MBq (5.2 +/- 0.2 mCi) [(18)F]SPA-RQ.

85 sulfur colloid-labeled meal and 7.4 MBq (0.2 mCi) of (111)In-DTPA in 120 mL of water.

86 uid study (300 mL of water with 7.4 MBq [0.2 mCi] of (111)In-diethylenetriaminepentaacetic acid) was

87 ( approximately 7.4 MBq [ approximately 0.2 mCi]) into 3 healthy volunteers and then performing dual

88 The activities ranged from 81.4 MBq (2.2 mCi) to 1,406 MBq (38 mCi) over the volume range of 3-9

89 ical purity (>99%), specific activity of 2.2 mCi/mg of NP, and high stability (i.e., no detectable di

90 its of 3.72 GBq (101 mCi) and 2.45 GBq (66.2 mCi), respectively.

91 uct ( approximately 74 MBq [ approximately 2 mCi]) and (131)I-OIH ( approximately 7.4 MBq [ approxima

92 mer ( approximately 74 MBq [ approximately 2 mCi]) and 7.4-11.1 MBq (200-300 micro Ci) of (131)I-OIH

93 Approximately 74 MBq (2 mCi) of (99m)Tc(CO)(3)(NTA) were coinjected with 9.25 MB

94 infarcted myocardium, we injected 74 MBq (2 mCi) of (99m)Tc-sestamibi (Cardiolite) intravenously 48

95 With a dose of 2 mCi/kg Bi, further trials using radioimmunotherapy with

96 Fifteen patients received a tracer (1 to 2 mCi) and therapeutic injection (10 to 20 mCi) of intra-O

97 patients (n = 27) received 185-740 MBq (5-20 mCi/m(2)) of (90)Y-J591.

98 ation were (18)F-FDG dose (259-740 MBq [7-20 mCi]) uptake time (45-90 min), sedation (never to freque

99 Dose limiting toxicity (DLT) was seen at 20 mCi/m(2), with two patients experiencing thrombocytopeni

100 The technique involved injecting 20 mCi MIBI 1 hour before the surgical procedure in patient

101 ximum, 740 MBq [20 mCi/1.7 m(2); maximum, 20 mCi]) of (11)C-methionine intravenously.

102 d by imaging the bath containing 740 MBq (20 mCi) (99m)Tc.

103 egan 5-15 min after injection of 740 MBq (20 mCi) per 1.7 m(2) of body surface area.

104 eived 740 MBq/1.7 m(2) (maximum, 740 MBq [20 mCi/1.7 m(2); maximum, 20 mCi]) of (11)C-methionine intr

105 tomography procedure: after injection of 20 mCi of [(11)C]flumazenil, dynamic emission images of the

106 o 2 mCi) and therapeutic injection (10 to 20 mCi) of intra-Ommaya 131I-3F8.

107 graphy and gamma imaging after a 740-mBq (20-mCi) technetium 99m sestamibi injection.

108 Dose-limiting toxicity was reached at the 20-mCi dose, when transient elevations in intracranial pres

109 GBq (140 mCi) in 3%, less than 7.4 GBq (200 mCi) in 8%, and less than 9.25 GBq (250 mCi) in 19%.

110 mpiric administered activity of 7.4 GBq (200 mCi) would exceed the MTA in 8%-15% of patients less tha

111 ) of (18)F-fluoride, more than 7.4 GBq (>200 mCi) of (18)F-AMBF3-TATE were obtained in 25 min (n = 5)

112 tely 50-60% and specific activities of >2000 mCi/micromol.

113 fter intravenous injection of 7.77 MBq (0.21 mCi) of (18)F-FDG per kilogram, a standard whole-body CT

114 fter intravenous injection of 7.77 MBq (0.21 mCi) of 18F-FDG per kilogram of body weight, PET emissio

115 was escalated from 444 to 777 MBq/kg (12-21 mCi/kg) using a 3 + 3 design.

116 , where the second infusion was capped at 21 mCi/kg.

117 ic administration of 1,739-8,066 MBq (47-218 mCi) of (131)I.

118 a specific activity that is greater than 220 mCi/mmol.

119 se of Tc-99 administered was 1.157 +/- 0.230 mCi.

120 Two dogs receiving 2.26 and 3.25 mCi/kg of (213)Bi rejected their grafts at day +127 and

121 aging 3 h after FDG administration (13 to 25 mCi), after which carotid plaque FDG uptake was determin

122 ities ranging from 5.55 to 9.25 GBq (150-250 mCi).

123 nistered activities of 7.4-9.25 GBq (200-250 mCi) frequently exceeded the calculated MTA in patients

124 (200 mCi) in 8%, and less than 9.25 GBq (250 mCi) in 19%.

125 a lowering of MTA to less than 9.25 GBq (250 mCi) were age at dosimetry greater than 45 y, the female

126 However, administration of 9.25 GBq (250 mCi) would exceed the MTA in 22% of patients less than 7

127 ty-six patients were treated with 102 to 298 mCi (3774-11 026 MBq) 131I, delivering an estimated 5.3

128 s than 150,000/microL received a dose of 0.3 mCi/kg.

129 fic activities of 37-111 MBq microg(-1) (1-3 mCi microg(-1)).

130 s after a bolus of approximately 48 MBq (1.3 mCi) (18)F-FDG were performed in rats anesthetized with

131 (control) was done by injecting 48 MBq (1.3 mCi) of (99m)Tc-MAG3, and renography was performed.

132 ups, all dogs conditioned with less than 1.3 mCi/kg Bi rejected their grafts.

133 min with specific activities as high as 2.3 mCi/nmol (97.5% radiochemical yield) is presented.

134 whereas dogs receiving (213)Bi doses of 3.3 mCi/kg or greater achieved high level donor chimerism.

135 3 radiotracer injection is 2,487.6 MBq (67.3 mCi).

136 were administered (intravenously) 111 MBq (3 mCi) of (125)I-DCIBzL, 111 MBq (3 mCi) of (125)I-NaI, an

137 111 MBq (3 mCi) of (125)I-DCIBzL, 111 MBq (3 mCi) of (125)I-NaI, an equivalent amount of nonradiolabe

138 ravenous administration of either 111 MBq (3 mCi) or 370 MBq (10 mCi) of florbetapir F 18 in patients

139 of patients, respectively, and after the 0.3-mCi/kg dose, these grade 4 toxicities occurred in 35%, 1

140 eaningful differences between the 111-MBq (3-mCi) and 370-MBq (10-mCi) dose in the visual rating or S

141 abel-recommended dose of 740-1100 MBq (20-30 mCi) of technetium 99m-sestamibi is estimated to involve

142 After injection with 25-30 mCi (925-1110 MBq) of technetium 99m sestamibi, patients

143 q) in all; therapeutic doses were 150 and 30 mCi (5,550 and 1,110 MBq), each to half of the patients.

144 wn whether low-dose radioiodine (1.1 GBq [30 mCi]) is as effective as high-dose radioiodine (3.7 GBq

145 rst fraction in each cycle was 1,110 MBq (30 mCi) of (131)I conjugated to 5 mg of antibody.

146 ved an administered activity of 1110 MBq (30 mCi), and 2 developed toxicity that required stem cell i

147 ing administered activities of 1,110 MBq (30 mCi); administered activities of 2,775 MBq (75 mCi) or m

148 erwent BSGI with intravenous injection of 30 mCi (1110 MBq) of technetium 99 ((99m)Tc)-sestamibi and

149 A total of 30 mCi 99mTc-sestamibi was injected at one minute into the

150 Multiple doses of 30 mCi/m(2) are well tolerated.

151 uppression; however, up to three doses of 30 mCi/m(2) could be safely administered.

152 specific activity was 85 GBq/micromol (2,300 mCi/micromol) (end of synthesis).

153 and toxicity of treatment with 11.1 GBq (300 mCi) of (131)I-MIBG per cycle.

154 Treatment comprised 11.1 GBq (300 mCi) per course and minimum intervals of 3 mo.

155 (131)I-MIBG at a fixed dose of 11.1 GBq (300 mCi) per cycle is safe and offers effective palliation o

156 ent disease received 0.4 mCi/kg (maximum, 32 mCi/kg) (9)(0)Y-ibritumomab tiuxetan, fludarabine, and 2

157 %) with high specific radioactivities (>3300 mCi/mumol).

158 itumomab ranged from 629 to 1,258 MBq (17-34 mCi).

159 specific activity of 12.9 GBq/micromol (349 mCi/micromol, n=7) at the end of synthesis.

160 ishing the recommended cumulative dose as 36 mCi/kg.

161 ged from 81.4 MBq (2.2 mCi) to 1,406 MBq (38 mCi) over the volume range of 3-9 mL.

162 ls) were labeled with 11.1-14.8 MBq (0.3-0.4 mCi) of (111)In-oxyquinoline and then injected into the

163 atients with persistent disease received 0.4 mCi/kg (maximum, 32 mCi/kg) (9)(0)Y-ibritumomab tiuxetan

164 At the maximum tolerated dose (0.4 mCi/kg [14.8 MBq/kg]), TTP and DR in complete responders

165 > or = 150,000/microL received a dose of 0.4 mCi/kg of (90)Y-ibritumomab tiuxetan, whereas those with

166 ial in which (90)Y-ibritumomab tiuxetan (0.4 mCi/kg) was added to the fludarabine, cyclophosphamide c

167 Zevalin (0.4 mCi/kg) was given to responders not in CR before transpl

168 at least twice the conventional dose of 0.4 mCi/kg, a weight-based strategy at 0.8 mCi/kg would have

169 e 90Y ibritumomab tiuxetan (14.8 MBq/kg [0.4 mCi/kg]) followed by high-dose BEAM.

170 An administered activity of 1.72 GBq (46.4 mCi) delivered the putative MTD of 27.25 Gy to the lungs

171 with averaged 803 +/- 200 MBq (21.7 +/- 5.4 mCi) of (99m)Tc injected at stress.

172 A total of 4 mCi (148 MBq) of FDG was administered before the procedu

173 After the 0.4-mCi/kg dose, grade 4 neutropenia, thrombocytopenia, and

174 for the 14-min acquisition or 125.8-MBq (3.4-mCi) injected dose for the 10-min acquisition.

175 ved an administered activity of 1480 MBq (40 mCi), and 2 developed hematologic toxicity that required

176 cific activity of 1,051 GBq/micromol (28,400 mCi/micromol; n=5) at the end of synthesis.

177 rived organ mass compared with 16.0 GBq (433 mCi) that would otherwise have been given had therapy be

178 an administered activity of 17 MBq/kg (0.45 mCi/kg), the effective dose equivalent was about 5 mSv o

179 ges of (18)F-PEG(6)-IPQA up to 128 MBq (3.47 mCi) per injection should be safe for administration in

180 n administration of less than 1,780 MBq (<48 mCi) of (11)C-NPA yields an organ dose of under 50 mSv (

181 udy, after diagnostic doses of 2, 1, and 0.5 mCi (74, 37, and 18.5 MBq), mean 2-d Rx/Dx values in 24,

182 g of surgery (1-d protocol) or 18.5 MBq (0.5 mCi) on the afternoon before surgery (2-d protocol).

183 s were treated with mAb 6D2 labeled with 1.5 mCi (1 Ci = 37 GBq) of the beta-emitter 188-Rhenium (188

184 Only one dog conditioned with 1.5 mCi/kg Bi-anti-TCRalphabeta had stable engraftment, wher

185 The recommended dose for (90)Y-J591 is 17.5 mCi/m(2).

186 Tumor-bearing mice were treated with 2.5 mCi (18)F-FDG, which is equivalent to the physiological

187 One hour after administration of 2.0-2.5 mCi (74.0-93.5 MBq) of fluorodeoxyglucose, 5-minute PET

188 successively at one of four dose levels: 2.5 mCi/m(2) (92.5 MBq/m(2); level 1), 5.0 mCi/m(2) (185 MBq

189 re injected with 2.22 +/- 0.19 GBq (60 +/- 5 mCi) of (82)Rb and imaged dynamically for 6 min at rest

190 ), 5.0 mCi/m(2) (185 MBq/m(2); level 2), 7.5 mCi/m(2) (277.5 MBq/m(2); level 3), and 10.0 mCi/m(2) (3

191 hours after tracer injection (mean dose, 9.5 mCi +/- 3.4 [standard deviation] [351.5 MBq +/- 125.8];

192 lone, GLV-1h153 and (131)I ( approximately 5 mCi), (131)I alone, or PBS, and followed for tumor growt

193 (90)Yttrium ((90)Y; 15 mCi/m(2))/(111)In (5 mCi)-DOTA-biotin was injected 24 hours later.

194 the intravenous administration of 185 MBq (5 mCi) (123)I-ADAM.

195 ter intravenous administration of 185 MBq (5 mCi) (99m)Tc-pertechnetate.

196 ter intravenous administration of 185 MBq (5 mCi) of (123)I-ADAM.

197 the intravenous administration of 185 MBq (5 mCi) of (123)I-IMPY.

198 mg of cG250 antibody labeled with 185 MBq (5 mCi) of (131)I.

199 Patients received 185 MBq (5 mCi) of (89)Zr-IAB2M and Df-IAB2M at total mass doses of

200 erwent injection of approximately 185 MBq (5 mCi) of (99m)Tc-tetrofosmin at peak stress, followed by

201 -J591) (2 mg of J591 labeled with 185 MBq [5 mCi] of (111)In via the chelating agent DOTA).

202 iodine-131 tositumomab (dosimetric dose of 5 mCi on day -19 and therapeutic dose of 0.75 Gy on day -1

203 Patients received 5 mCi BMIPP within 30 h of symptom cessation.

204 atients underwent dosimetry (day -21) with 5 mCi (185 MBq) 111In-ibritumomab tiuxetan following 250 m

205 The 17.5-mCi/m(2) dose level was determined to be the MTD.

206 nt level would correspond to a 92.5-MBq (2.5-mCi) injected dose for the 14-min acquisition or 125.8-M

207 n scan followed by injection of 1.85 GBq (50 mCi) H(2)(15)O and dynamic scanning for 5 min were acqui

208 achieve the target RMI ranged from 22 to 50 mCi/kg, with cumulative RMI of 3.2 to 8.92 Gy.

209 mCi/kg or with a total dose greater than 500 mCi.

210 1)I administered activities of 19.2 GBq (520 mCi) after adjustment for CT-derived organ mass compared

211 of [131I]tositumomab (median, 19.4 Gbq [525 mCi]; range, 12.1 to 42.7 Gbq [328 to 1,154 mCi]) to del

212 of high specific activity (2.1 GBq/mmol, 58 mCi/mmol) (1 Ci = 37 GBq) and no detectable dilution of

213 Activity of 7.4-22.2 MBq (0.2-0.6 mCi) localized within the synthetic lesion.

214 he injection of 669 +/- 97 MBq (18.1 +/- 2.6 mCi) of 11C-DASB.

215 PA group after administration of 96 MBq (2.6 mCi) of the tracer.

216 ects were injected with 170-244 MBq (4.6-6.6 mCi) of BMS747158 intravenously.

217 edian 90Y-ibritumomab tiuxetan dose was 71.6 mCi (2649.2 MBq; range, 36.6-105 mCi; range, 1354.2-3885

218 rmed with a bolus injection of 2,220 MBq (60 mCi) of 15O-water, which was followed by a 370-MBq (10 m

219 Repeat dosing at 45 to 60 mCi/m(2) was associated with dose-limiting myelosuppress

220 for THW vs. 4,958 +/- 2,294 MBq [134 +/- 62 mCi] for rhTSH), THW was associated with a lower rate of

221 le-body retention was scaled to 2.44 GBq (66 mCi) to give the same dose rate of 43.6 rad/h in the lun

222 activities of 200 +/- 26 MBq/mg (5.4 +/- 0.7 mCi/mg) were obtained, with > or =95% of the radioactivi

223 1.4 to 2.1 mCi/kg Bi-anti-CD45 or 2.0 to 2.7 mCi/kg Bi-anti-TCRalphabeta.

224 was dose limiting at 75 mCi/m(2), and the 70-mCi/m(2) dose level was determined to be the single-dose

225 (n = 28) received 370-2,775 MBq/m(2) (10-75 mCi/m(2)) of (177)Lu-J591 and 5 groups of patients (n =

226 Myelosuppression was dose limiting at 75 mCi/m(2), and the 70-mCi/m(2) dose level was determined

227 i); administered activities of 2,775 MBq (75 mCi) or more were associated with symptoms in 40% of pat

228 eescalation study in 15 dogs with 2.7 to 0.8 mCi/kg Bi.

229 f 0.4 mCi/kg, a weight-based strategy at 0.8 mCi/kg would have resulted in a wide range of RAD; nearl

230 nistered activity per patient (36.5 vs. 23.8 mCi, P < 0.0001).

231 on Drug Research Committee is 1.58 GBq (42.8 mCi).

232 ftment was achieved with doses of 3.6 to 8.8 mCi/kg Bi, but signs of liver toxicity were noted in all

233 completion of the ablation, an additional 8 mCi (296 MBq) of FDG was administered to assess ablation

234 An 8-mCi (+/-10%) dose of (18)F FSPG was given to five subjec

235 ole-body retention threshold of 2.96 GBq (80 mCi) at 48 h has been used to limit the radioactivity of

236 The MTD of (131)I-ch81C6 is 2.96 GBq (80 mCi) because of dose-limiting hematologic toxicity.

237 toxicity defined the MTD to be 2.96 GBq (80 mCi) for all patients, regardless of treatment strata.

238 ns the administered activity to 2.96 GBq (80 mCi) whole-body retention at 48 h after administration t

239 is pediatric patient, where the 2.96-GBq (80 mCi) whole-body retention was scaled to 2.44 GBq (66 mCi

240 inical (82)Rb injection of 2 x 1,480 MBq (80 mCi) would result in a mean effective dose of 3.7 mSv us

241 f the adult female reference phantom when 80 mCi of (131)I are in the body and 90% of this is uniform

242 In this work, the 80-mCi activity retention limit is used to derive lung-abso

243 The implications of the 80-mCi rule are also examined.

244 A dose-rate-based version of the 80-mCi rule is derived and used to demonstrate application

245 With this definition, the 80-mCi rule was generalized by calculating the activity req

246 ed activity (5,661 +/- 2,997 MBq [153 +/- 81 mCi] for THW vs. 4,958 +/- 2,294 MBq [134 +/- 62 mCi] fo

247 herapy ranged from 38 to 67 GBq (1,030-1,810 mCi).

248 labeled anti-CD45 mAb (dose (213)Bi=2.26-4.9 mCi/kg) in six to eight injections.

249 hy (PET) and CT (hereafter, PET/CT) with 6.9 mCi of fluorodeoxyglucose (FDG) and magnetic resonance (

250 was 15.1 +/- 10.8 mGy/MBq (55.8 +/- 39.8 cGy/mCi) 90Y-hMN-4 IgG (n = 29 tumors in 8 patients), with a

251 Average dosimetry ratio (Gy/mCi) of the therapy/tracer administration was 0.88 (+/-

252 9 mrad/mCi]; female, 0.033 mGy/MBq [122 mrad/mCi]).

253 , the kidneys (male, 0.035 mGy/MBq [131 mrad/mCi]; female, 0.042 mGy/MBq [155 mrad/mCi]), and the bon

254 1 mrad/mCi]; female, 0.042 mGy/MBq [155 mrad/mCi]), and the bone marrow (male, 0.024 mGy/MBq [89 mrad

255 by the liver (male, 0.045 mGy/MBq [167 mrad/mCi]; female, 0.064 mGy/MBq [238 mrad/mCi]), the kidneys

256 7 mrad/mCi]; female, 0.064 mGy/MBq [238 mrad/mCi]), the kidneys (male, 0.035 mGy/MBq [131 mrad/mCi];

257 2 mrad/mCi]; female, 0.174 mGy/MBq [646 mrad/mCi]), followed by the liver (male, 0.045 mGy/MBq [167 m

258 s the bladder (male, 0.179 mGy/MBq [662 mrad/mCi]; female, 0.174 mGy/MBq [646 mrad/mCi]), followed by

259 he bone marrow (male, 0.024 mGy/MBq [89 mrad/mCi]; female, 0.033 mGy/MBq [122 mrad/mCi]).

260 as, 2.4 muGy/MBq (19, 19, 10.4, and 8.9 mrad/mCi, respectively).

261 ffective dose was 5.7 microSv/MBq (21.1 mrem/mCi).

262 and 32.3 microSv/MBq (109, 108, and 120 mrem/mCi), respectively.

263 and 0.033 +/- 0.012 mSv/MBq (121 +/- 43 mrem/mCi) for a standard female patient.

264 was 0.028 +/- 0.012 mSv/MBq (103 +/- 43 mrem/mCi) for a standard male patient and 0.033 +/- 0.012 mSv

265 dose was approximately 17 muSv/MBq (62 mrem/mCi), with the gallbladder receiving the highest dose of

266 fective dose was 6.98 microGy/MBq (25.8 mrem/mCi).

267 0020 mGy/MBq (0.0086, 0.0006, and 0.0074 rad/mCi) for the ovaries, testes, and red marrow, respective

268 295 rad/mCi) and 0.00709 mGy/MBq (0.0262 rad/mCi), respectively.

269 and spleen were 0.00797 mGy/MBq (0.0295 rad/mCi) and 0.00709 mGy/MBq (0.0262 rad/mCi), respectively.

270 s, with a dose of 0.0393 mGy/MBq (0.1455 rad/mCi).

271 0.0002 to 0.0393 mGy/MBq (0.0006-0.1455 rad/mCi).

272 ecreases with a value of 7.5 mGy/MBq (28 rad/mCi) for a newborn.

273 adder wall dose to 0.0885 mGy/MBq (0.327 rad/mCi) or 0.128 mGy/MBq (0.473 rad/mCi), respectively, and

274 eceived an average of 0.12 mGy/MBq (0.43 rad/mCi) (range, 0.098-0.15 mGy/MBq).

275 (0.327 rad/mCi) or 0.128 mGy/MBq (0.473 rad/mCi), respectively, and the effective dose to 0.0149 mSv

276 large intestines (161.26 muGy/MBq [0.597 rad/mCi] and 184.59 muGy/MBq [0.683 rad/mCi]).

277 .597 rad/mCi] and 184.59 muGy/MBq [0.683 rad/mCi]).

278 less than the value of 0.45 mGy/MBq (1.7 rad/mCi) previously accepted.

279 d gallbladder wall, 0.193 mGy/MBq (0.716 rad/mCi).

280 ated in this study of 0.21 mGy/MBq (0.77 rad/mCi) is approximately a factor of 2 less than the value

281 the highest dose (229.50 muGy/MBq [0.849 rad/mCi]), followed by the small and large intestines (161.2

282 inary bladder wall, 0.258 mGy/MBq (0.955 rad/mCi), and gallbladder wall, 0.193 mGy/MBq (0.716 rad/mCi

283 The blood absorbed dose (cGy/37 MBq [rad/mCi] administered) was reduced from 2.54 +/- 0.91 (mean

284 t-specific mean 90Y dose (cGy/37 MBq, or rad/mCi) was 0.53 (0.32-0.78) to whole body, 3.75 (0.63-6.89

285 se equivalent was 0.0106 mSv/MBq (0.0392 rem/mCi).

286 effective dose to 0.0149 mSv/MBq (0.0551 rem/mCi) or 0.0171 mSv/MBq (0.0634 rem/mCi), respectively.

287 .0551 rem/mCi) or 0.0171 mSv/MBq (0.0634 rem/mCi), respectively.

288 effective dose was 0.019 mSv/MBq (0.072 rem/mCi).

289 effective dose was 0.025 mSv/MBq (0.0922 rem/mCi).

290 effective dose was 28.79 muGy/MBq (0.107 rem/mCi).

291 fective dose of (18)F-FPPRGD2 was 0.1462 rem/mCi +/- 0.0669 (0.0396 mSv/MBq +/- 0.0181).

292 by the heart wall at 0.048 mSv/MBq (0.18 rem/mCi).

293 of 2.01 x 10(-2) mSv/MBq (7.43 x 10(-2) rem/mCi).

294 e was the kidneys at 0.066 mSv/MBq (0.24 rem/mCi), followed by the heart wall at 0.048 mSv/MBq (0.18

295 g model) and uptake in the spleen (0.250 rem/mCi +/- 0.168 [0.068 mSv/MBq +/- 0.046]) and large intes

296 ary clearance through the kidneys (0.360 rem/mCi +/- 0.185 [0.098 mSv/MBq +/- 0.050]) and bladder (0.

297 h an effective dose of 0.41 mSv/MBq (1.5 rem/mCi).

298 q +/- 0.046]) and large intestine (0.529 rem/mCi +/- 0.236 [0.143 mSv/MBq +/- 0.064]).

299 work is approximately 0.16 mSv/MBq (0.60 rem/mCi).

300 dder wall (ca. 180 +/- 30 mSv/MBq or 0.7 rem/mCi with a 2.4 h void interval) suggests that multiple s

301 8 mSv/MBq +/- 0.050]) and bladder (0.862 rem/mCi +/- 0.436 [0.233 mSv/MBq +/- 0.118], voiding model)

302 tients, but no correlation of Rx/Dx with the mCi in the diagnostic dose was seen.